Canalis Pharmaceuticals

Canalis Pharmaceuticals was a private biotechnology company focused on the discovery and development of novel small molecule therapies for rare and serious skeletal diseases. The company's research centered on activating natural bone-forming pathways to treat conditions characterized by bone fragility, such as osteogenesis imperfecta. Founded and incubated by Frazier Healthcare Partners, Canalis leveraged proprietary insights into bone biology to advance its lead program, CK-0101. In February 2020, the company was acquired by UCB to strengthen UCB's metabolic bone disease pipeline. The acquisition integrated Canalis's small molecule expertise with UCB's existing portfolio of bone health biologics.